low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact ability to raise capital and may delay patient enrollment if healthcare access is constrained. Biotech sector sentiment is more correlated with risk appetite than economic fundamentals.

Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-12+ years out for potential commercialization). Clinical-stage biotechs with no earnings are particularly sensitive to rate changes as their entire value is based on discounted terminal values. Higher rates also increase cost of capital for future financing rounds and make risk-free alternatives more attractive to investors, reducing speculative capital flows into biotech.

growth - Attracts highly speculative, risk-tolerant investors seeking asymmetric returns from binary clinical trial outcomes. Typical shareholders include biotech-focused hedge funds, venture capital, and retail investors with high risk tolerance. Not suitable for value or income investors given lack of earnings, dividends, or tangible book value. Momentum traders enter around data catalyst events.